Background {#Sec1}
==========

Ankylosing spondylitis (AS) is a chronic progressive inflammatory disorder that predominantly involves the axial skeleton, possibly causing sacroiliitis, spondylitis, spondylodiscitis, enthesitis and arthritis of the zygoapophyseal, costovertebral and costosternal joints \[[@CR1]\]. In the late stage of AS, thoracolumbar kyphosis often occurs.

Pain, stiffness and fatigue are cardinal complaints in AS patients \[[@CR2], [@CR3]\]. These clinical symptoms and subsequent disease progression result in substantial functional limitations, gradual loss of spinal mobility and impairment of quality of life (QoL). Health-related QoL measurement objectively reflects the actual effect of the disorder on an individual and the degree of suffering \[[@CR4], [@CR5]\]. Knowing which aspects of QoL are most affected by a particular disease is helpful for both researchers and clinicians to identify the disease-related problems that may be inadvertently neglected in the research or clinical practice \[[@CR6]\]. Also, the medical outcomes survey short form-36 (SF-36) has been frequently and widely used for rheumatologic and musculoskeletal disorders \[[@CR7]--[@CR10]\]. In previous studies, SF-36 is the most commonly used measurement technique to assess the health-related QoL of AS patients \[[@CR10]--[@CR18]\]. Among these studies, the relationship between QoL and disease activity or functional status has been investigated by many researchers \[[@CR13]--[@CR16]\]. However, relatively fewer studies focused on the relationship between spinal mobility and QoL measured by SF-36 in AS \[[@CR13], [@CR17], [@CR18]\].

First reported in 1980, the Oswestry Disability Index (ODI) is a validated and well- accepted measure of the impact of back pain or leg pain on disability \[[@CR19]\]. Moreover, ODI has been widely used for the clinical evaluation of AS patients \[[@CR20]--[@CR22]\]. However, the relationship between ODI and QoL in AS patients remains unknown so far.

To our best knowledge, a limited number of cases were enrolled in most of the previous studies which focused on the QoL in AS patients. Furthermore, no studies have specifically investigated the relationship between the disability measured by ODI and QoL in AS patients. In addition, the correlation between global kyphosis (GK) in lateral plain radiographs and QoL in AS patients still remains unclear.

The aim of the study was to evaluate QoL and correlation with clinical and radiographic variables in AS patients, especially to figure out the relationship between the pain-related disability measured by ODI, GK and QoL.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

The study was conducted in compliance with the Helsinki Declaration to protect human subjects and was approved by the Medical Ethics Committee of Medical School of Nanjing University (the ethics approval number provided by the board was 2,011,052). Written informed consent was obtained from all patients prior to testing. Study participants were recruited from outpatients and inpatients of spine surgery department of one tertiary referral hospital in China. Between January 2008 and November 2015, 245 consecutive patients who fulfilled the modified New York criteria for AS were included \[[@CR23]\]. Among these patients, 120 patients received drug therapy in the clinic and 125 patients were admitted for spinal surgery for correction of thoracolumbar kyphosis. Patients with concomitant disorders such as serious infections or chronic diseases (cardiac, respiratory, gastro-intestinal, neurological, endocrine, etc) were excluded. Patients with spinal surgery history were also excluded to eliminate the effect of prior spinal surgery on clinical variables and QoL.

The information of patients were collected by two trained orthopaedic residents using identical questionnaires including demographic information (age, gender, age at onset, disease duration), disease-specific characteristics (overall pain, fatigue, degree and duration of morning stiffness, low back pain-related disability, peripheral arthritis, nonsteroidal antiinflammatory drugs (NSAIDs) and anti-tumor necrosis factor (TNF) drugs intake, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Human leukocyte antigen (HLA)-B27, GK), measurements for disease activity, functional status, spinal mobility, global assessment and health-related QoL.

Disease specific instruments {#Sec4}
----------------------------

The Bath Ankylosing Disease Activity Index (BASDAI) was used to evaluate disease activity \[[@CR24]\]. The self-administered instrument consists of six questions, dealing with fatigue, spinal pain, joint pain and swelling, areas of localized tenderness and the severity and duration of morning stiffness. Functional status was assessed by Bath Ankylosing Spondylitis Functional Index (BASFI) \[[@CR25], [@CR26]\], which consists of 10 scales: eight visual analogue scales dealing with physical function and two scales reflecting the patient's ability to deal with daily activities. Meanwhile, physical examinations were performed by orthopaedic residents to determine the patient's physical mobility, including cervical rotation, tragus-to-wall distance, forward flexion (modified Schober index), lateral lumbar flexion, intermalleolar distance and the five physical parameters constitute the Bath Ankylosing Spondylitis Metrology Index (BASMI) score \[[@CR27]\]. Bath Ankylosing Spondylitis Global Score (BAS-G) is comprised of two items questioning the effect of the disease on the patients' overall well-being over the previous week and during the 6 months, respectively. The BASDAI, BASFI, BASMI and BAS-G scores have a final range from 0 to 10 and the higher scores of each parameter indicate higher disease activity, worse functional status, worse physical mobility and worse patients' global assessment, respectively \[[@CR28]\]. The ODI is a self-administered questionnaire measuring "back-specific function" on a 10 item scale with 6 response categories each. The 10 items include pain intensity, personal care, lifting, walking, sitting, standing, sleeping, sex life, social life, and traveling. Each item scores from 0 to 5. The total score of the ODI is calculated by adding all scores of applicable items, dividing the obtained score with the maximal total score and by multiplying the result for 100% to obtain a percentage score \[[@CR19]\]. The total score of the index ranges from 0 to 100% and a higher score indicates more severe disability. Overall pain, fatigue and the severity and duration of morning stiffness were assessed by Visual Analogue Scale (VAS). All VAS were 10-cm horizontal lines.

Generic instrument {#Sec5}
------------------

Health-related QoL was evaluated by SF-36 consisting of 36 items, a generic instrument measuring eight different aspects of health status. The items of the SF-36 are grouped into eight subscales: physical functioning (10 items), role limitation due to physical health problems (4 items), bodily pain (2 items), general health perception (5 items), vitality (4 items), social functioning (2 items), role limitation due to emotional problems (3 items) and mental health (5 items). The first four subscales are combined to produce one summary measure: a Physical Component Summary (PCS) and the second four subscales are combined to produce another summary measure: a Mental Component Summary (MCS). These 35 questions are associated with the health status during the period of the last 4 weeks. The questionnaire also includes a single item that provides information about the assessment of the current health condition in comparison to the health condition a year ago. Items are scored in the range from 0 to 100 and a higher score means a better health status. The SF-36 takes about 5--10 min to complete \[[@CR7], [@CR8]\].

Laboratory and radiographic measurements {#Sec6}
----------------------------------------

Acute-phase reactants, including ESR and CRP levels were measured. ESR was measured by standard Westergren method (normal range 0-20 mm/h) and CRP by the immunoturbidimetric method (normal range 0-8 mg/L).

Long-cassette standing lateral radiographs of the spine were taken for measurements. GK was defined as the angle between the superior endplate of the maximally tilted upper end vertebra and the inferior endplate of the maximally tilted lower end vertebra \[[@CR29]\]. Two groups were divided by GK: mild kyphotic group (GK \< 70°,*n* = 176) and severe kyphotic group (GK ≥ 70°,*n* = 69) \[[@CR30]\]. The difference of disease activity, functional status, spinal mobility and QoL between mild kyphotic and severe kyphotic groups was compared.

Statistical analysis {#Sec7}
--------------------

The Spearman rank correlation test was applied to test correlations. Continuous variables were compared by Student's t test. Hierarchal multiple regression analysis was used to investigate the contributions of demographic, clinical, laboratory and radiographic variables to physical function (PF) subscale of SF-36. To decrease the influence of other kind of parameters, we entered the variables in three successive conceptual blocks: (1) demographic variables, (2) laboratory and radiographic variables, and (3) clinical variables. Stepwise multiple regression analysis was then performed to identify the major contributors to PF subscale of SF-36. Collinearity diagnostics was applied to ensure that no multicollinearity existed in these two models. All statistical analyses were done using SPSS 19 (SPSS,USA). Descriptive data were presented as mean and standard deviation for continuous variables and as frequencies and percentages for categorical variables. A value of *P \<* 0.05 was considered to be statistically significant.

Results {#Sec8}
=======

Patient characteristics {#Sec9}
-----------------------

Two hundred and 45 patients (223 males and 22 females) with an average age

of 36.2 ± 10.9 years (range, 17--66 years) were enrolled in this study. Demographic, clinical, laboratory and radiographic characteristics of the study population are listed in Table [1](#Tab1){ref-type="table"}. Mean age at the onset of symptoms was 24.7 ± 8.7 years (range, 8--57 years) and mean disease duration was 11.4 ± 8.0 years (range, 0--39 years). The ESR of 119 (49%) patients and the CRP of 176 (72%) patients were above normal range, respectively. Almost all the patients had a positive HLA-B27 allele (92%). Sixty-nine (28%) patients were severe kyphotic. Ninety-three (38%) patients had BASDAI ≥ 4. Mean BASFI and BASMI value were 3.2 (range 0--10) and 4.6 (range 0--10), respectively.Table 1Demographic, clinical, laboratory and radiographic characteristics of enrolled AS patientsCharacteristicsMean (SD) or frequencies (percentages)RangeAge (years)36.2 (10.9)17--66Male patients, n (%)223 (91)Age at onset (years)24.7 (8.7)8--57Disease duration (years)11.4 (8.0)0--39Overall pain VAS (0-10 cm)3.8 (2.3)0--10Fatigue VAS (0-10 cm)4.1 (2.4)0--10Morning stiffness (degree) VAS (0-10 cm)3.8 (2.9)0--10Morning stiffness (duration) (0-120 min)36.7 (32.9)0--120ODI (%) (0--100)31.8 (19.7)0--94Peripheral arthritis, n (%)109 (44)NSAIDs intake, n (%)156 (64)Anti-TNF drugs intake, n (%)19 (8)ESR (mm/h)27.0 (19.1)2--126CRP (mg/L)24.7 (20.6)0.2--128.4HLA-B27+, n (%)226 (92)GK (degrees)61.0 (18.7)22--122BASDAI (0--10)3.5 (2.0)0--9BASFI (0--10)3.2 (2.6)0--10BASMI (0--10)4.6 (3.1)0--10BAS-G (0--10)5.0 (2.6)0--10*VAS* Visual Analogue Scale, *ODI* Oswestry Disability Index, *NSAIDs* Nonsteroidal Antiinflammatory Drugs, *TNF* tumor necrosis factor, *ESR* erythrocyte sedimentation rate, *CRP* C-reactive protein, *HLA-B27* Human leukocyte antigen-B27, *GK* global kyphosis, *BASDAI* Bath ankylosing spondylitis disease activity index, *BASFI* Bath ankylosing spondylitis functional index, *BASMI* Bath Ankylosing Spondylitis Metrology Index, *BAS-G* Bath Ankylosing Spondylitis Global Score

Mean scores for SF-36 subscales are shown in Table [2](#Tab2){ref-type="table"}. Most affected subscales of SF-36 in AS patients were role physical (30.00 ± 39.02) and general health (35.19 ± 21.40). The physical component summary scale of SF-36 was significantly more impaired than the mental component summary scale (44.21 ± 20.79 vs. 54.19 ± 20.47; *P* \< 0.001).Table 2Summary of each SF-36 subscale, physical component and mental component summary scaleMean (SD)RangePhysical function (PF)60.36 (25.01)0--100Role physical (RP)30.00 (39.02)0--100Bodily pain (BP)51.22 (22.07)0--100General health (GH)35.19 (21.40)0--100Vitality (VT)54.96 (17.78)0--100Social function (SF)58.19 (23.11)0--100Role emotional (RE)41.09 (43.93)0--100Mental health (MH)62.52 (18.83)12--100Physical component summary (PCS)44.21 (20.79)1.25--95Mental component summary (MCS)54.19 (20.47)7.25--97.50

Relationship between BASDAI, BASFI, BASMI, ODI and SF-36 subscales {#Sec10}
------------------------------------------------------------------

The scores of BASDAI, BASFI, BASMI and ODI had significant negative correlations with all SF-36 subscales. BASDAI had the strongest correlation with bodily pain (*r* = −0.616, *P* \< 0.001). BASFI, BASMI and ODI were most correlated with PF subscale (*r* = −0.669, −0.523, and −0.725, respectively, *P* \< 0.001) (Table [3](#Tab3){ref-type="table"}).Table 3Correlations between BASDAI, BASFI, BASMI, ODI and SF-36 subscalesBASDAIBASFIBASMIODI*rPrPrprp*Physical function−0.394\<0.001−0.669\<0.001−0.523\<0.001−0.725\<0.001Role physical−0.345\<0.001−0.471\<0.001−0.277\<0.001−0.447\<0.001Bodily pain−0.616\<0.001−0.554\<0.001−0.298\<0.001−0.689\<0.001General health−0.274\<0.001−0.318\<0.001−0.224\<0.001−0.443\<0.001Vitality−0.380\<0.001−0.396\<0.001−0.227\<0.001−0.388\<0.001Social function−0.292\<0.001−0.466\<0.001−0.296\<0.001−0.554\<0.001Role emotional−0.315\<0.001−0.328\<0.001−0.1690.008−0.328\<0.001Mental health−0.319\<0.001−0.288\<0.001−0.1730.007−0.378\<0.001*BASDAI* Bath ankylosing spondylitis disease activity index, *BASFI* Bath ankylosing spondylitis functional index, *BASMI* Bath Ankylosing Spondylitis Metrology Index, *ODI* Oswestry Disability Index

Comparison of BASDAI, BASFI, BASMI and SF-36 subscales between mild Kyphotic group and severe Kyphotic group {#Sec11}
------------------------------------------------------------------------------------------------------------

Statistically, no significant difference was found for BASDAI between mild kyphotic and severe kyphotic groups (*P* = 0.726). BASFI and BASMI scores of severe kyphotic group were significantly higher than those of mild kyphotic group, respectively (*P* = 0.005 and *P* = 0.001, respectively) (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Comparison of BASDAI, BASFI and BASMI between mild kyphotic group (GK \< 70°) and severe kyphotic group (GK ≥ 70°). BASFI and BASMI were significantly different between groups. \*: *P* \< 0.05

The quality of life of severe kyphotic group was worse than that of mild kyphotic group. The score of PF subscale in severe kyphotic group was significantly lower than those in mild kyphotic group (*P* \< 0.05). There was no significant difference in other subscales of SF-36, PCS and MCS between the two groups (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Comparison of SF-36 subscales between mild kyphotic group (GK \< 70°) and severe kyphotic group (GK ≥ 70°). Only PF was significanly different between groups. \*: *P* \< 0.05

Contributors and non-contributors to physical function (PF) {#Sec12}
-----------------------------------------------------------

The independent variables including demographic, clinical, laboratory and radiographic variables were entered into the analysis in the following models to investigate the factors contributing variance to PF.

Results of hierarchic multiple regression analysis of the factors in relation to PF are shown in Table [4](#Tab4){ref-type="table"}. Model 1 (demographic variables model) describes the contribution of demographic variables to PF. These variables contributed an overall *R* ^2^ of 6.8% (*P* \< 0.05).Model 2 (laboratory and radiographic variables model)evaluates the contributions of laboratory and radiographic variables to PF. These variables increased 5.5% in the *R* ^2^ value (*R* ^2^ = 12.3%). Only CRP contributed significantly to PF in this model (*P* \< 0.05). Model 3 (clinical variables model) shows the standard multiple regression analysis and all of the investigated variables were entered into the model to assess their contributions to PF. ODI (*P* \< 0.001) and BASFI (*P* \< 0.001) were significant determinants of PF. An additional 50.4% of the variance in PF was added by the clinical variables. The whole model could explain 62.7% of the total variance in PF.Table 4Hierarchic multiple regression analysis of demographic, clinical, laboratory and radiographic variables in relation to physical function (PF)Model 1Model 2Model 3Standardized coefficient *P*Standardized coefficient *P*Standardized coefficient *P*Age−0.1040.191−0.1290.105−0.0660.231Gender−0.1340.033−0.0970.123−0.0300.483Disease duration−0.1350.087−0.1360.0840.0290.581ESR−0.0050.944−0.0230.633CRP−0.2150.0030.0190.698GK−0.1180.0710.0020.958Overall pain (VAS)−0.0400.486Morning stiffness (degree) (VAS)0.0840.306Morning stiffness (duration) (min)−0.0860.192Fatigue (VAS)−0.0530.442ODI−0.432\<0.001BASDAI0.1230.224BASFI−0.366\<0.001BASMI−0.1060.054BASG−0.0040.953*R* ^*2*^ (%)6.812.362.7Adjusted *R* ^*2*^ (%)5.610.160.2F24.29723.71715.778*ESR* erythrocyte sedimentation rate, *CRP* C-reactive protein, *GK* global kyphosis, *VAS* Visual Analogue Scale, *ODI* Oswestry Disability Index, *BASDAI* Bath ankylosing spondylitis disease activity index, *BASFI* Bath ankylosing spondylitis functional index, *BASMI* Bath Ankylosing Spondylitis Metrology Index, *BAS-G* Bath Ankylosing Spondylitis Global Score*Model 1* demographic variables model, *Model 2* laboratory and radiographic variables model, *Model 3* clinical variables model

Major contributors to physical function (PF) {#Sec13}
--------------------------------------------

The results of multiple stepwise regression analysis in PF are shown in Table [5](#Tab5){ref-type="table"}. Higher ODI (B = −0.548, *P* \< 0.001), BASFI (B = −3.303, *P* \< 0.001) and BASMI (B = −0.969, *P* \< 0.001) score were significantly associated with lower PF score. These variables could explain 61.3% of variance in PF. The analysis indicated that ODI (standardized coefficient = −0.431) contributed most in predicting PF statistically.Table 5Stepwise multiple regression analysis with physical function (PF) subscale as dependent variableIndependent variables*B*Standardized coefficient*tPR* ^*2*^ (%)Overall model61.3ODI−0.548−0.431−7.641\<0.001BASFI−3.303−0.337−5.617\<0.001BASMI−0.969−0.119−2.3930.017*ODI* Oswestry Disability Index, *BASFI* Bath ankylosing spondylitis functional index, *BASMI* Bath Ankylosing Spondylitis Metrology Index

Discussion {#Sec14}
==========

Ankylosing spondylitis (AS) is characterized by inflammatory back pain and bony fusion of the axial skeleton \[[@CR1]\]. It may lead to irreversible structural damage and the consequent reduction in functional status, limitation of physical mobility and poor QoL. The present study aimed to investigate QoL and correlation with disease activity, functional status, spinal mobility in AS patients.

In the current study, around 75% of the AS patients developed the first symptoms at an age which was younger than 30 years and less than 3% (around 2.4%) of patients had the onset age which was older than 45 years, which is similar to previous studies \[[@CR1], [@CR31]\]. In consideration of the above mentioned findings, AS is likely to develop in the early adulthood and affects patients in their most productive age which has posed a long-standing burden on both the individual and society, thus requiring a close attention. The peripheral joint involvement of AS in the previous studies is present in 20--51% of patients \[[@CR16], [@CR32]\]. In the current study, 45% of the patients had peripheral arthritis at a similar rate to the literature, and hips were the most commonly affected joints, confirming previous studies \[[@CR33], [@CR34]\].

With regard to QoL, our results were in line with previous studies by Ozgul et al. \[[@CR3]\] and Vesović-Potić et al. \[[@CR13]\], showing that role physical was the most affected subscale of SF-36, whereas mental health and physical function were least affected in AS patients, which was similar to the results of previous studies \[[@CR12]\]. Some published literatures also indicated that AS affected mostly physical subscales of SF-36 \[[@CR13], [@CR14], [@CR18], [@CR35]\], which was supported by our findings: physical component summary (PCS) was significantly more impaired than mental component summary (MCS).

BASDAI, BASFI and BASMI with proven reliability and validity are commonly and widely used in the clinical assessment of AS patients \[[@CR24], [@CR25], [@CR27]\]. In the present study, BASDAI and BASFI scores were significantly and negatively correlated with all SF-36 subscales. Likewise, Özdemir \[[@CR18]\] reported that BASDAI and BASFI had significant negative correlations with all SF-36 subscales except for general health. On the contrary, some researchers \[[@CR15]\] found BASDAI was only correlated with general health significantly and BASFI had a significant correlation only with emotional role. In the current study, BASDAI was most correlated with bodily pain, which is in line with the published results by Bodur et al. \[[@CR36]\]. Similar to previous studies \[[@CR18], [@CR36]\], BASFI had the strongest correlation with physical function subscale of SF-36. The current study indicated that BASMI was also correlated with all of the subscales of SF-36, which is in accordance with the results reported by Bodur et al. \[[@CR36]\]. However, a few studies \[[@CR13], [@CR17]\] reported that only two subscales (physical functioning and general health) of SF-36 were negatively correlated with BASMI index, which may be owing to the relatively small sample size of these studies. Considering these findings, the disease-specific instruments (BASDAI, BASFI, BASMI) for AS correlated well with the generic instrument (SF-36) and it could be concluded that the broad scope of SF-36 might reflect the health status in AS populations adequately and accurately.

In advanced stage of AS, patients often develop thoracolumbar or cervical kyphosis. The GK is a radiographic parameter which is used to evaluate the severity of kyphosis in sagittal plane \[[@CR29], [@CR30], [@CR37]\]. Decreased volume of thoracic and abdominal cavity caused by the increased GK will cause the compression of important organs (heart, lung, intestine, etc) and further lead to cardiopulmonary and gastrointestinal dysfunction. In addition, the increased GK will lead to enhanced muscle tension of the back and severe fatigue, thus impairing the QoL. Shin et al. \[[@CR20]\] investigated the correlation between clinical outcome and spinopelvic parameters in AS, but they did not evaluated the relationship between GK and clinical variables. Moreover, few studies reported the relationship between GK and QoL evaluated by SF-36 in AS patients. Our study showed that AS patients in severe kyphotic group had significantly higher BASFI and BASMI scores than those in mild kyphotic group. Compared to mild kyphotic group, patients in severe kyphotic group had significantly lower score in physical function subscale of SF-36. These results suggested that development of kyphotic deformity might contribute to impairment of physical function and spinal mobility. Therefore, the prevention of GK progression in early stage and correction of GK in advanced stage are crucial for the treatment of AS. However, no significant difference was observed for BASDAI between these two groups, the possible explanation might be that the degree of disease activity was not always consistent with the severity of kyphosis in AS, which meant that an AS patient with severe kyphosis did not necessarily have high disease activity.

PF subscale of SF-36 describes the limitations in performing physical activities due to the deterioration of physical health \[[@CR38]\] and it has been identified as a main outcome domain in AS \[[@CR26], [@CR39]\]. Limitations in physical function may influence the ability to remain in employment and to participate in leisure and domestic activities. Also, the ability to fulfill social roles in family and society may thereby be restricted, thus influencing the person's emotional state \[[@CR11]\]. Therefore, the whole well-being of patients would be disrupted. To date, no studies have weighed the relative impact of demographic, radiographic, laboratory and clinical variables on PF in a hierarchical regression model in AS patients. In the current study, it was noted that each model made significant contributions to PF (*P* \< 0.05). In demographic model, gender contributed significantly to PF (*P* = 0.033). The standardized coefficient was negative which meant female patients experienced lower PF score than males. Previous studies investigating gender-attributable differences with respect to QoL in AS have also shown that female gender was associated with lower QoL \[[@CR40]--[@CR43]\]. However, they mainly showed lower QoL in females regarding mental health, rather than physical health \[[@CR40]\]. In laboratory and radiographic model, only CRP contributed significantly to PF (standardized coefficient = −0.215, *P* = 0.003) which suggested that increased CRP level was correlated with decreased PF. Similarly, it was revealed by Cansu et al. \[[@CR44]\] that elevated CRP was associated with poor functional status. These findings indicated that the reduction of CRP level was helpful to the improvement of physical function in AS patients. Clinical variables made the most contribution to PF after correction for other factors, adding an additional 50.4% of the variance in PF. Multiple stepwise regression analysis was also applied to investigate major contributors to PF in AS patients, showing that BASFI and BASMI were the independently associated factors with PF. Similarly, Vesović-Potić et al. \[[@CR13]\] developed a regression model to identify variables associated with physical function subscale of SF-36 and reported that BASFI score was the independently associated factor. Besides, Ariza-Ariza et al. \[[@CR14]\] reported that spinal mobility (evaluated by BASMI) was the main factor associated with PF in AS patients. With proven reliability and validity, ODI has become one of the most commonly used measures of disability in back pain \[[@CR45]--[@CR48]\]. However, few studies have investigated the relationship between the pain-related disability measured by ODI and QoL in AS patients. In the present study, significant negative correlations were observed between ODI and all SF-36 subscales. Notably, ODI was also a major contributor to PF in the multiple stepwise regression model. It seems reasonable because both ODI and PF evaluate the problems associated with physical activities in daily life. In consideration of these findings, effective treatment of low back pain and valid management strategies to slow the progressive loss of spinal mobility were beneficial to the improvement of QoL. In the current study, BASDAI was not a major predictor of PF. However, in contrast to our study, Fernández-Carballido et al. \[[@CR49]\] suggested that disease activity (measured by BASDAI) was a major determinant of QoL and physical function in patients with axial spondyloarthritis (including AS). One possible explanation of the distinct results might be that the patients enrolled in their study were in early stage of the disorder, during which period physical function was significantly influenced by pain, fatigue and stiffness just evaluated by BASDAI.

The limitations of the present study should be acknowledged. Firstly, the current study is a retrospective design. Secondly, with our department specializing in spine deformity correction, much more kyphotic patients who needed surgery came to our center. It is possible that the proportion of advanced AS patients is high in this study, leading to research bias (e.g. worse clinical and radiographic outcomes). Further prospective longitudinal studies are required to establish the definitive relationship between various clinical outcomes and QoL, and identify the correlation between radiographic parameters and QoL in AS patients from different populations.

Conclusions {#Sec15}
===========

The present study demonstrated that impaired QoL is significantly correlated with high disease activity, poor functional status and decreased spinal mobility in AS patients. GK may be an important radiographic parameter that affects functional status, spinal mobility and QoL in AS patients. ODI, BASFI, BASMI are the major contributors to PF subscale of SF-36. Understanding these complex relationships in AS patients is of utmost importance for both physicians and surgeons to facilitate counseling and management of AS.
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